ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
December 16, 2021Merck announced that the European Commission (EC) has approved VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18... -
FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults
July 20, 2021(NYSE: MRK) today announced the FDA approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes -
Single vaccination approach developed to combat respiratory diseases
May 24, 2019Scientists have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections.
Pharma Sources Insight January 2025
